Indaptus sets up $100M share-selling facility with H.C. Wainwright
What's the deal? Indaptus TherapeuticsDealroom has a profile for this one. Try Dealroom → (Nasdaq: INDP) has entered a new "at the market" (ATM) offering agreement with H.C. Wainwright & Co.Dealroom has a profile for this one. Try Dealroom → that could raise up to $100 million in gross proceeds through the sale of its common stock. The clinical-stage biopharmaceutical company signed the deal on August 28, 2026.
How it works: The agreement lets Indaptus issue shares directly into the market at prevailing prices, up to $100 million, subject to available authorized shares and eligibility on Form S-3. H.C. Wainwright, acting as sales agent, earns a placement fee of 3% of gross sales proceeds.
The new Sales Agreement replaces a June 1, 2022 agreement. Sales under the prior deal do not count toward the new $100 million limit.
Why now? ATM facilities are a common financing tool for clinical-stage biopharma firms, giving them flexibility to fund research and development over time. Indaptus filed a prospectus supplement on August 31, 2026, amended on September 4.
What's the catch? Indaptus is not obligated to sell any shares and can suspend the offering at any time; it has not indicated immediate plans to draw down. Any sales, though, would dilute existing shareholders.
The signal: At $100 million, the facility ranks in the lower half of comparable raises — around the 38th percentile by size. For a small-cap developer, though, the deal buys optionality: capital on tap without the commitment or dilution of a single large offering.
Read more: minichart.com.sg
Image credit: Generated with Gemini
